<p>Aardvark Therapeutics, Inc.（纳斯达克代码：AARD - 获取免费报告）在周四的午盘交易中股价上涨了 2.5%。该股票最高交易价格为 15.44 美元，最后交易价格为 15.35 美元。午盘交易中大约交易了 158,013 股，较平均每日交易量 202,695 股下降了 22%。该股票之前的收盘价为 14.98 美元。</p>
<p>获取 <strong>Aardvark Therapeutics</strong> 的提醒：</p>
<h2>分析师评级上调和下调</h2>
<p>几位股票研究分析师最近对 AARD 股票发表了看法。Oppenheimer 在 12 月 23 日的研究报告中开始覆盖 Aardvark Therapeutics 的股票。他们给予该公司的 “跑赢大盘” 评级，并设定了 35.00 美元的目标价。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Aardvark Therapeutics 的 “卖出（d-）” 评级。加拿大皇家银行在 11 月 14 日的报告中将 Aardvark Therapeutics 的目标价从 19.00 美元下调至 18.00 美元，并给予该公司 “跑赢大盘” 评级。Cantor Fitzgerald 在 11 月 14 日的研究报告中重新发布了对 Aardvark Therapeutics 的 “增持” 评级。最后，William Blair 在 12 月 12 日的研究报告中开始覆盖 Aardvark Therapeutics 的股票。他们对该股票给予了 “跑赢大盘” 的评级。一位股票研究分析师给予该股票 “强烈买入” 评级，十位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 32.70 美元。</p>
<p><strong>查看我们关于 AARD 的最新研究报告</strong></p>
<h2>Aardvark Therapeutics 股票表现</h2>
<p>该股票的市值为 3.3417 亿美元，市盈率为-7.24。该公司的 50 日移动平均价格为 12.49 美元，200 日移动平均价格为 12.06 美元。</p>
<p>Aardvark Therapeutics（纳斯达克代码：AARD - 获取免费报告）最近在 11 月 13 日公布了其财报。该公司报告本季度每股收益为（0.75 美元），超出分析师共识预期的（0.82 美元）0.07 美元。</p>
<h2>Aardvark Therapeutics 的内部交易</h2>
<p>在相关消息中，首席财务官 Nelson Sun 在 12 月 11 日的交易中购买了 3,000 股 Aardvark Therapeutics 的股票。该股票的平均购买价格为每股 14.40 美元，总交易额为 43,200.00 美元。交易完成后，首席财务官直接持有该公司 108,484 股股票，价值 1,562,169.60 美元。这代表其持股增加了 2.84%。该购买在向 SEC 提交的文件中披露，文件可通过此超链接访问。此外，首席执行官 Tien-Li Lee 在 12 月 11 日的交易中购买了 7,000 股该公司的股票。该股票的平均购买价格为每股 14.48 美元，总价值为 101,360.00 美元。交易完成后，首席执行官持有该公司 1,551,613 股股票，价值 22,467,356.24 美元。该交易代表其持股增加了 0.45%。该购买的披露信息可在 SEC 文件中找到。</p>
<h2>Aardvark Therapeutics 的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近修改了对该公司的持股。Millennium Management LLC 在第三季度购买了 Aardvark Therapeutics 的新头寸，价值为 4,248,000 美元。Cresset Asset Management LLC 在第三季度购买了 Aardvark Therapeutics 的新股份，价值约为 1,951,000 美元。Vanguard Group Inc.在第三季度将其在 Aardvark Therapeutics 的持股提高了 20.6%。Vanguard Group Inc.目前拥有该公司 555,721 股股票，价值 7,386,000 美元，此前在该期间内又购买了 94,744 股。Geode Capital Management LLC 在第二季度将其在 Aardvark Therapeutics 的持股提高了 129.7%。Geode Capital Management LLC 目前拥有该公司 136,927 股股票，价值 1,851,000 美元，此前在上个季度又购买了 77,327 股。最后，Citadel Advisors LLC 在第三季度将其在 Aardvark Therapeutics 的持股提高了 5.9%。Citadel Advisors LLC 目前拥有该公司 1,359,883 股股票，价值 18,073,000 美元，此前在该期间内又购买了 76,151 股。</p>
<h2>关于 Aardvark Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Aardvark Therapeutics, Inc 是一家总部位于马萨诸塞州剑桥的临床阶段生物制药公司，专注于小分子调节剂的发现和开发，这些调节剂作用于视黄酸受体相关孤儿受体伽马（RORγ）。RORγ在 T 辅助细胞 17（Th17）细胞分化和炎症过程中发挥核心作用。通过靶向这一转录因子，Aardvark 旨在解决一系列自身免疫和免疫介导的疾病。</p>
<p>该公司的主要项目包括选择性 RORγ反向激动剂，旨在抑制在银屑病、炎症性肠病和其他慢性炎症性疾病等情况下由病理性 Th17 驱动的反应。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Aardvark Therapeutics</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这四个简单步骤 “防止” 你的银行账户受到美联储影响</li>
<li>几乎不为人知的人工智能公司解决万亿美元问题</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护你的财富</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Aardvark Therapeutics 吗？</h2>
<p>在考虑 Aardvark Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Aardvark Therapeutics 并不在名单上。</p>
<p>虽然 Aardvark Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AARD

<p>Aardvark Therapeutics（纳斯达克代码：AARD）股票在午盘交易中上涨 2.5%，至 15.35 美元，交易量较平均水平下降 22%。分析师的评级意见不一，Oppenheimer 设定的目标价为 35.00 美元，而 Weiss Ratings 则维持 “卖出” 评级。该股票的市值为 3.3417 亿美元，市盈率为-7.24。最近的内部购买包括首席财务官 Nelson Sun 和首席执行官 Tien-Li Lee。机构投资者也增加了对该公司的持股，该公司专注于开发自身免疫疾病的治疗方案</p>

<p>Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) shares were up 2.5% during mid-day trading on Thursday . The stock traded as high as $15.44 and last traded at $15.35. Approximately 158,013 shares were traded during mid-day trading, a decline of 22% from the average daily volume of 202,695 shares. The stock had previously closed at $14.98.</p>
<div class="lb-trans"><p>Aardvark Therapeutics, Inc.（纳斯达克代码：AARD - 获取免费报告）在周四的午盘交易中股价上涨了 2.5%。该股票最高交易价格为 15.44 美元，最后交易价格为 15.35 美元。午盘交易中大约交易了 158,013 股，较平均每日交易量 202,695 股下降了 22%。该股票之前的收盘价为 14.98 美元。</p>
</div><p>Get <strong>Aardvark Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Aardvark Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><p>Several equities research analysts recently weighed in on AARD shares. Oppenheimer began coverage on shares of Aardvark Therapeutics in a research report on Tuesday, December 23rd. They set an &#34;outperform&#34; rating and a $35.00 price target for the company. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Aardvark Therapeutics in a research report on Monday, December 29th. Royal Bank Of Canada reduced their price objective on Aardvark Therapeutics from $19.00 to $18.00 and set an &#34;outperform&#34; rating for the company in a report on Friday, November 14th. Cantor Fitzgerald reissued an &#34;overweight&#34; rating on shares of Aardvark Therapeutics in a research report on Friday, November 14th. Finally, William Blair began coverage on shares of Aardvark Therapeutics in a research note on Friday, December 12th. They set an &#34;outperform&#34; rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $32.70.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对 AARD 股票发表了看法。Oppenheimer 在 12 月 23 日的研究报告中开始覆盖 Aardvark Therapeutics 的股票。他们给予该公司的 “跑赢大盘” 评级，并设定了 35.00 美元的目标价。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Aardvark Therapeutics 的 “卖出（d-）” 评级。加拿大皇家银行在 11 月 14 日的报告中将 Aardvark Therapeutics 的目标价从 19.00 美元下调至 18.00 美元，并给予该公司 “跑赢大盘” 评级。Cantor Fitzgerald 在 11 月 14 日的研究报告中重新发布了对 Aardvark Therapeutics 的 “增持” 评级。最后，William Blair 在 12 月 12 日的研究报告中开始覆盖 Aardvark Therapeutics 的股票。他们对该股票给予了 “跑赢大盘” 的评级。一位股票研究分析师给予该股票 “强烈买入” 评级，十位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 32.70 美元。</p>
</div><p><strong>View Our Latest Research Report on AARD</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 AARD 的最新研究报告</strong></p>
</div><h2>Aardvark Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Aardvark Therapeutics 股票表现</h2>
</div><p>The stock has a market cap of $334.17 million and a PE ratio of -7.24. The company's 50-day moving average price is $12.49 and its 200 day moving average price is $12.06.</p>
<div class="lb-trans"><p>该股票的市值为 3.3417 亿美元，市盈率为-7.24。该公司的 50 日移动平均价格为 12.49 美元，200 日移动平均价格为 12.06 美元。</p>
</div><p>Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last announced its earnings results on Thursday, November 13th. The company reported ($0.75) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.07.</p>
<div class="lb-trans"><p>Aardvark Therapeutics（纳斯达克代码：AARD - 获取免费报告）最近在 11 月 13 日公布了其财报。该公司报告本季度每股收益为（0.75 美元），超出分析师共识预期的（0.82 美元）0.07 美元。</p>
</div><h2>Insider Transactions at Aardvark Therapeutics</h2>
<div class="lb-trans"><h2>Aardvark Therapeutics 的内部交易</h2>
</div><p>In related news, CFO Nelson Sun purchased 3,000 shares of Aardvark Therapeutics stock in a transaction on Thursday, December 11th. The stock was acquired at an average price of $14.40 per share, for a total transaction of $43,200.00. Following the completion of the transaction, the chief financial officer directly owned 108,484 shares in the company, valued at $1,562,169.60. This represents a 2.84% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Tien-Li Lee acquired 7,000 shares of the business's stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average price of $14.48 per share, with a total value of $101,360.00. Following the completion of the purchase, the chief executive officer owned 1,551,613 shares in the company, valued at $22,467,356.24. This trade represents a 0.45% increase in their position. The disclosure for this purchase is available in the SEC filing.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Nelson Sun 在 12 月 11 日的交易中购买了 3,000 股 Aardvark Therapeutics 的股票。该股票的平均购买价格为每股 14.40 美元，总交易额为 43,200.00 美元。交易完成后，首席财务官直接持有该公司 108,484 股股票，价值 1,562,169.60 美元。这代表其持股增加了 2.84%。该购买在向 SEC 提交的文件中披露，文件可通过此超链接访问。此外，首席执行官 Tien-Li Lee 在 12 月 11 日的交易中购买了 7,000 股该公司的股票。该股票的平均购买价格为每股 14.48 美元，总价值为 101,360.00 美元。交易完成后，首席执行官持有该公司 1,551,613 股股票，价值 22,467,356.24 美元。该交易代表其持股增加了 0.45%。该购买的披露信息可在 SEC 文件中找到。</p>
</div><h2>Institutional Trading of Aardvark Therapeutics</h2>
<div class="lb-trans"><h2>Aardvark Therapeutics 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC purchased a new position in shares of Aardvark Therapeutics during the 3rd quarter valued at $4,248,000. Cresset Asset Management LLC bought a new stake in Aardvark Therapeutics during the third quarter valued at about $1,951,000. Vanguard Group Inc. raised its holdings in Aardvark Therapeutics by 20.6% during the third quarter. Vanguard Group Inc. now owns 555,721 shares of the company's stock valued at $7,386,000 after acquiring an additional 94,744 shares during the period. Geode Capital Management LLC lifted its position in shares of Aardvark Therapeutics by 129.7% in the second quarter. Geode Capital Management LLC now owns 136,927 shares of the company's stock valued at $1,851,000 after acquiring an additional 77,327 shares in the last quarter. Finally, Citadel Advisors LLC boosted its stake in shares of Aardvark Therapeutics by 5.9% in the third quarter. Citadel Advisors LLC now owns 1,359,883 shares of the company's stock worth $18,073,000 after acquiring an additional 76,151 shares during the period.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近修改了对该公司的持股。Millennium Management LLC 在第三季度购买了 Aardvark Therapeutics 的新头寸，价值为 4,248,000 美元。Cresset Asset Management LLC 在第三季度购买了 Aardvark Therapeutics 的新股份，价值约为 1,951,000 美元。Vanguard Group Inc.在第三季度将其在 Aardvark Therapeutics 的持股提高了 20.6%。Vanguard Group Inc.目前拥有该公司 555,721 股股票，价值 7,386,000 美元，此前在该期间内又购买了 94,744 股。Geode Capital Management LLC 在第二季度将其在 Aardvark Therapeutics 的持股提高了 129.7%。Geode Capital Management LLC 目前拥有该公司 136,927 股股票，价值 1,851,000 美元，此前在上个季度又购买了 77,327 股。最后，Citadel Advisors LLC 在第三季度将其在 Aardvark Therapeutics 的持股提高了 5.9%。Citadel Advisors LLC 目前拥有该公司 1,359,883 股股票，价值 18,073,000 美元，此前在该期间内又购买了 76,151 股。</p>
</div><h2>About Aardvark Therapeutics</h2>
<div class="lb-trans"><h2>关于 Aardvark Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.</p>
<div class="lb-trans"><p>Aardvark Therapeutics, Inc 是一家总部位于马萨诸塞州剑桥的临床阶段生物制药公司，专注于小分子调节剂的发现和开发，这些调节剂作用于视黄酸受体相关孤儿受体伽马（RORγ）。RORγ在 T 辅助细胞 17（Th17）细胞分化和炎症过程中发挥核心作用。通过靶向这一转录因子，Aardvark 旨在解决一系列自身免疫和免疫介导的疾病。</p>
</div><p>The company's lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.</p>
<div class="lb-trans"><p>该公司的主要项目包括选择性 RORγ反向激动剂，旨在抑制在银屑病、炎症性肠病和其他慢性炎症性疾病等情况下由病理性 Th17 驱动的反应。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Aardvark Therapeutics</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>Virtually Unknown AI Company Solving Trillion-Dollar Problem</li>
<li>Do not delete, read immediately</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Aardvark Therapeutics</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这四个简单步骤 “防止” 你的银行账户受到美联储影响</li>
<li>几乎不为人知的人工智能公司解决万亿美元问题</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护你的财富</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aardvark Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Aardvark Therapeutics 吗？</h2>
</div><p>Before you consider Aardvark Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Aardvark Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aardvark Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及他们推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Aardvark Therapeutics 并不在名单上。</p>
</div><p>While Aardvark Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Aardvark Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Aardvark Therapeutics（NASDAQ:AARD）的股价上涨了 2.5% - 现在是买入的好时机吗？